??
交易撮合者擔(dān)心，債市動(dòng)蕩和全球不穩(wěn)定可能會(huì)影響2016年的并購活動(dòng)，今年的并購交易達(dá)到空前高位，超過2007年的峰值水平。
根據(jù)湯森路透(Thomson Reuters)的數(shù)據(jù)，受到制藥、能源和消費(fèi)行業(yè)并購急劇增加的推動(dòng)，已宣布并購交易總額升至4.6萬億美元，高于8年前的4.3萬億美元。
其中很多交易規(guī)模達(dá)到數(shù)百億甚至數(shù)千億美元，這些大規(guī)模并購包括制藥商輝瑞(Pfizer)和艾爾建(Allergan)、釀酒企業(yè)百威英博(AB InBev)和南非米勒啤酒(SABMiller)以及石油巨擘荷蘭皇家殼牌(Royal Dutch Shell)和英國天然氣集團(tuán)(BG Group)。
在疲弱經(jīng)濟(jì)環(huán)境下對增長的渴望、廉價(jià)融資以及維權(quán)股東繼續(xù)施壓提高回報(bào)，推動(dòng)很多公司合并。
交易撮合者表示，2016年，這些基本面因素仍會(huì)大體存在。然而，很多企業(yè)也警告稱，業(yè)內(nèi)同行日益擔(dān)心：一場像上月巴黎那樣的新的恐怖襲擊或者又一場金融危機(jī)可能損害企業(yè)信心，終結(jié)本輪并購行情。（中國進(jìn)出口網(wǎng)）
Dealmakers are worried that bond market turmoil and global instability could hit mergers and acquisitions in 2016 after deals reached an all-time high this year, surpassing 2007’s peak.
Driven by a surge of tie-ups in the pharmaceuticals, energy and consumer sectors, the total value of announced transactions has climbed to $4.6tn, compared with $4.3tn eight years ago, according to Thomson Reuters data.
Many of these deals have been for tens or hundreds of billions of dollars, including blockbuster tie-ups between drugmakers Pfizer and Allergan, brewers AB InBev and SABMiller, and oil majors Royal Dutch Shell and BG Group.
Hunger for growth in a weak economic environment, cheap financing and continued pressure from activist shareholders to boost returns drove many companies to combine.
Dealmakers have said these fundamentals remain broadly intact for 2016. However, many have also warned of growing fears among their peers that a fresh terror attack, like that in Paris last month, or another financial crisis could tarnish business confidence and bring the M&A run to an end.
